Literature DB >> 11918082

Synergistic effect of interleukin-2 and a vaccine of irradiated melanoma cells transfected to secrete staphylococcal enterotoxin A.

David P Schrayer1, Nicola Kouttab, Vincent J Hearing, Harold J Wanebo.   

Abstract

We have previously reported that immunization of mice with melanoma cells transfected to secrete the superantigen, Staphylococcal enterotoxin A (SEA), increased the production of antibodies to the B700 melanoma antigen, stimulated the production of endogenous interleukin 2 (IL-2), activated the expression of CD4, CD8 and CD25 T cell markers and enhanced NK cell activity. Now we show that immunization of mice with a vaccine of irradiated sea-transfected melanoma cells coupled with IL-2 therapy was even more effective in inhibiting the growth of primary melanoma tumors and the development of lung metastases than was the irradiated melanoma cell vaccine alone or IL-2 alone. The morphological and immunological effectiveness of the therapy was dose-dependent on IL-2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918082     DOI: 10.1023/a:1013875104326

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  48 in total

1.  Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo.

Authors:  H Belfrage; M Dohlsten; G Hedlund; T Kalland
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma.

Authors:  R H Shoemaker; D J Dykes; J Plowman; S D Harrison; D P Griswold; B J Abbott; J G Mayo; O Fodstad; M R Boyd
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

3.  Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (FECA) of murine melanoma.

Authors:  D Shrayer; J Koness; A Maizel; H Wanebo
Journal:  Melanoma Res       Date:  1992-05       Impact factor: 3.599

4.  Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.

Authors:  J P McLaughlin; J Schlom; J A Kantor; J W Greiner
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

5.  Monoclonal antibody production to a B16 melanoma associated antigen.

Authors:  Y Tomita; P M Montague; V J Hearing
Journal:  Int J Cancer       Date:  1985-04-15       Impact factor: 7.396

6.  Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.

Authors:  D P Shrayer; H Bogaars; V J Hearing; H J Wanebo
Journal:  J Exp Ther Oncol       Date:  1996-03

7.  Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12.

Authors:  Q H Nguyen; R L Roberts; B J Ank; S J Lin; C K Lau; E R Stiehm
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

8.  Costimulation regulates the kinetics of interleukin-2 response to bacterial superantigens.

Authors:  E Muraille; S Devos; K Thielemans; J Urbain; M Moser; O Leo
Journal:  Immunology       Date:  1996-10       Impact factor: 7.397

9.  The effects of interleukin-2 on bone marrow engraftment in a murine model.

Authors:  S P Ho; G R Hafez; W B Ershler
Journal:  Lymphokine Cytokine Res       Date:  1991-06

10.  Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine.

Authors:  D Shrayer; N Kouttab; A Maizel; H Wanebo; V J Hearing; D M Gersten
Journal:  Int J Cancer       Date:  1993-02-20       Impact factor: 7.396

View more
  1 in total

1.  Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.

Authors:  M Lotem; E Shiloni; I Pappo; O Drize; T Hamburger; R Weitzen; R Isacson; L Kaduri; S Merims; S Frankenburg; T Peretz
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.